Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
Thursday, January 05, 2023Fate Therapeutics Inc a clinicalstage biopharmaceutical company dedicated to bringing a firstinclass pipeline of induced pluripotent stem cell iPSCderived cellular immunotherapies to patients with cancer and autoimmune disorders announced today that...
EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines
Thursday, January 05, 2023EyePoint Pharmaceuticals Inc a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders today announced a business update and key clinical timelines for its lead...
Sartorius Collaborates with RoosterBio to Advance Downstream Purification Processes for the Manufacture of Exosomes
Thursday, January 05, 2023The life science group Sartorius extended a strategic collaboration partnership agreement with RoosterBio Inc RoosterBio to address purification challenges and establish scalable downstream manufacturing processes for exosomebased therapies Through t...
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant
Wednesday, January 04, 2023Jasper Therapeutics Inc a biotechnology company focused on transforming the field of hematopoietic cell transplant HCT therapies today announced that the European Medicines Agency EMA Committee for Orphan Medicinal Products COMP has granted orphan dr...
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
Wednesday, January 04, 2023Nuvectis Pharma Inc a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology today announced a collaboration with the European Ne...
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Tuesday, January 03, 2023The Janssen Pharmaceutical Companies of Johnson Johnson today announced the submission of a Marketing Authorisation Application MAA to the European Medicines Agency EMA seeking approval of talquetamab for the treatment of patients with relapsed or r...
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
Tuesday, January 03, 2023Aurinia Pharmaceuticals Inc announces it has entered into a settlement agreement with Sun Pharmaceutical Industries Inc Sun Pharmaceuticals Industries Ltd and Sun Pharma Global FZE
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
Wednesday, December 28, 2022Biostage Inc a clinicalstage biotechnology company developing regenerativemedicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer trauma or birth defects today announced that it had selected IQVIA a leadi...
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
Thursday, December 22, 2022Ceapro Inc a growthstage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries today announced it has received approval from Health Canada to initiate its Phase a study eva...
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
Thursday, December 22, 2022Neurocrine Biosciences Inc a leading neurosciencefocused biopharmaceutical company today announced that the US Food and Drug Administration FDA has accepted its supplemental New Drug Application sNDA for valbenazine as a treatment for chorea associat...
